Clinical Trial Update: Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202 [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 study evaluating the safety, tolerability, and pharmacokinetic/pharmacodynamic profile of the investigational …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 3-202

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED